S280: B-CELL MALIGNANCIES TREATED WITH TARGETED DRUGS AND SARS-COV-2 INFECTION. A EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA). (23rd June 2022)

• Record Type: Journal Article
• Authors: Infante, M. S.; Salmanton-García, J.; Fernandez-Cruz, A.; Marchesi, F.; RÁČIL, Z.; Hanakova, M.; Jaksic, O.; Weinbergerova, B.; Besson, C.; Duarte, R.; Itri, F.; VALKOVIĆ, T.; Busca, A.; Guidetti, A.; GLENTHØJ, A.; Collins, G.; Bonuomo, V.; Sili, U.; Seval, G.; Machado, M.; Lopez-Garcia, A.; Cordoba, R.; Blennow, O.; Abu-zeinah, G.; Lemure, S.; Kulasekararaj, A.; Falces-Romero, I.; Cattaneo, C.; Cornely, O. A.; Hernandez-Rivas, J.-A.; Pagano, L.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 181
• Page End: 182
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000844012.13018.0a
• Languages: English
• ISSNs: 2572-9241